The authors demonstrated efficient delivery of bromodomain-containing protein 4 (BRD4) siRNA to KG1 cells and in ex vivo primary AML patient derived samples, which resulted in downregulation at mRNA and protein levels. The gene discussed is BRD4; the disease is acute myeloid leukemia.